X|Chem and Kymera expand partnership to 12 targets

More than 50 target hypotheses generated in <12 months | 7 novel targets advanced to the research pipeline in 2023 ... expansion and novel target ...

Recent advances in targeting the “undruggable” proteins: from drug ...

... targeting cysteine 12 (C12) in KRASG12C. One compound, named XY-4-88 ... Hopefully, the scope of drug targets will expand with future ...

Targeted protein degradation: current molecular targets, localization ...

TPD has expanded its focus beyond well-established targets. •. A diverse range ... partner, CDK12 and cyclin K, are simultaneously targeted for degradation.

News - Sanofi Ventures

“This partnership provides an exciting opportunity to expand Sanofi's ... Targets Beyond Neurodegeneration Into Fragile X Syndrome (FXS). Jun 25, 2024.

Kymera Therapeutics Announces FDA Clearance of Investigational ...

Image for Leerink Partners resumed coverage on Kymera Therapeutics with a new price target ... Kymera's expanding pipeline. "At Kymera, we ...

Kymera Therapeutics, Inc. (KYMR) Price Targets - Zacks

... X (Expanded) Industries based on their average Zacks Rank. An industry with ... made by 17 brokerage firms. What is Kymera Therapeutics, Inc.'s 12 month price ...

NEOsphere Biotechnologies Partners with Kymera Therapeutics for ...

By combining Kymera's exceptional drug discovery capabilities with our ability to swiftly identify and proteomically validate novel targets, ...

FDA Approves Kymera Therapeutics' IND Application for Novel Oral ...

... x IL-4 x STAT6 target, including 6 indications, 1 R&D institution involved, and as many as 177 patents. The drug KT-621 is a small molecule ...

FORM 10-K - SEC Filing – C4 Therapeutics, Inc.

... increase if Biogen extends the collaboration term and elects additional targets. ... target toxicity, or other mechanisms of drug toxicity including chemical ...

Astellas Strikes Another Deal to Expand in Cancer, Partnering With ...

Targeted protein degradation is a hot field. Kymera Therapeutics and Arvinas are among the biotech companies developing small molecules for ...

NJ Bio, Inc. — Targeted Protein Degraders

uSMITE™ targeted protein degradation platform, Undisclosed ... Strategic partnership (8-year extension and expansion of collaboration) ...

Kymera Therapeutics Announces First Quarter 2024 Financial

“This was an important quarter for Kymera as we are poised to expand our clinical pipeline with an increased focus on immunology. With our STAT6 ...

KT-413 - Drug Hunter

12 minute read. Aug. 27, 2024. A Targeted Protein Degrader of IRAK4 and IMiD Substrates for the Treatment of Diffuse ... Chem., 2024 Kymera Therapeutics, ...

PROTAC targeted protein degraders: the past is prologue | Arvinas

We then discuss key areas for the future of TPD, including establishing the target classes for which TPD is most suitable, expanding the use of ubiquitin ...

Kymera Therapeutics Announces Third Quarter 2023 Financial ...

First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; ...

Small Molecules for Cancer Targets | Sept 30 - Oct 3, 2024

Biortus also offers catalog proteins via VWR, Cayman, FisherSci, and several other partners. Session Break12:40 pm. DEGRADERS ...

Vertex follows pharma lead in bet on protein degradation

Per deal terms, Kymera will be responsible for initial research activities on disease targets covered by the collaboration. Once a candidate ...

Kymera Therapeutics Announces Third Quarter 2023 Financial ...

First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; ...

Targeted protein degradation: a new pharmacology paradigm?

Another form of TPD technology is the lysosome-based TPD autophagy-targeting chimera ... Evotec and Bristol Myers Squibb extend and expand strategic partnership ...

Recent Advances in PROTACs for Drug Targeted Protein Research

... expand the drug space of the target. So far, PROTACs have been ... Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC) Chem.